Vera Therapeutics, Inc. (VERA)
Largest Insider Buys in Sector
VERA Stock Price History Chart
VERA Stock Performance
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode …
Insider Activity of Vera Therapeutics, Inc.
Over the last 12 months, insiders at Vera Therapeutics, Inc. have bought $5M and sold $69.93M worth of Vera Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Vera Therapeutics, Inc. have bought $44.26M and sold $24.59M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Katabi Maha (director) — $10M.
The last purchase of 161,290 shares for transaction amount of $5M was made by Katabi Maha (director) on 2024‑01‑30.
List of Insider Buy and Sell Transactions, Vera Therapeutics, Inc.
| 2024-12-18 | Sale | PRESIDENT AND CEO | 17,500 0.0289% | $43.07 | $753,680 | -0.60% | ||
| 2024-12-11 | Sale | PRESIDENT AND CEO | 17,500 0.0277% | $46.94 | $821,523 | -5.38% | ||
| 2024-11-25 | Sale | PRESIDENT AND CEO | 19,375 0.0313% | $47.98 | $929,560 | +0.45% | ||
| 2024-11-13 | Sale | PRESIDENT AND CEO | 30,625 0.048% | $49.50 | $1.52M | -4.37% | ||
| 2024-10-28 | Sale | director | 15,000 0.0323% | $48.03 | $720,493 | 0.00% | ||
| 2024-10-23 | Sale | PRESIDENT AND CEO | 19,375 0.0351% | $40.39 | $782,610 | 0.00% | ||
| 2024-10-09 | Sale | PRESIDENT AND CEO | 15,625 0.0239% | $38.24 | $597,568 | +19.09% | ||
| 2024-09-25 | Sale | PRESIDENT AND CEO | 22,225 0.0419% | $46.02 | $1.02M | -0.77% | ||
| 2024-09-19 | Sale | director | 13,823 0.0254% | $42.31 | $584,793 | +5.26% | ||
| 2024-09-18 | Sale | director | 2,653 0.005% | $42.01 | $111,440 | +9.41% | ||
| 2024-09-11 | Sale | PRESIDENT AND CEO | 15,625 0.0285% | $37.50 | $585,934 | 0.00% | ||
| 2024-08-28 | Sale | PRESIDENT AND CEO | 30,320 0.0555% | $36.84 | $1.12M | +16.70% | ||
| 2024-08-21 | Sale | PRESIDENT AND CEO | 14,471 0.0263% | $39.76 | $575,425 | +6.81% | ||
| 2024-08-14 | Sale | PRESIDENT AND CEO | 15,625 0.03% | $37.56 | $586,927 | 0.00% | ||
| 2024-05-16 | Sale | SVP, FINANCE, CHIEF ACCT OFFCR | 20,651 0.037% | $42.32 | $873,890 | -4.69% | ||
| 2024-05-15 | Sale | SVP, FINANCE, CHIEF ACCT OFFCR | 10,186 0.0184% | $42.27 | $430,546 | -6.44% | ||
| 2024-04-10 | Sale | SVP, FINANCE, CHIEF ACCT OFFCR | 5,714 0.01% | $40.00 | $228,560 | -3.74% | ||
| 2024-04-03 | Sale | CHIEF FINANCIAL OFFICER | 118,477 0.2156% | $39.58 | $4.69M | +1.06% | ||
| 2024-03-25 | Sale | director | 340,000 0.6089% | $40.50 | $13.77M | -2.62% | ||
| 2024-03-22 | Sale | director | 413,450 0.7439% | $40.51 | $16.75M | -2.07% |
Insider Historical Profitability
| COMMODORE CAPITAL LP | 10 percent owner | 4400000 6.9485% | $42.60 | 1 | 1 | +20.13% |
| Katabi Maha | director | 2793987 4.4123% | $42.60 | 2 | 3 | +57.41% |
| SEIDENBERG BETH C | director | 131553 0.2077% | $42.60 | 19 | 3 | +96.5% |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 51206 0.0809% | $42.60 | 2 | 3 | +91.54% |
| Grant Sean | CHIEF FINANCIAL OFFICER | 0 0% | $42.60 | 4 | 1 | +32.83% |
Institutional Investor Ownership
| Avoro Capital Advisors Llc | $227.03M | 9.63 | 5.26M | New | +$227.03M | 2.72 | |
| BlackRock | $143.11M | 6.07 | 3.32M | +20.48% | +$24.32M | <0.01 | |
| Commodore Capital, LP | $136.47M | 5.79 | 3.17M | -41.93% | -$98.53M | 0.52 | |
| Fidelity Investments | $134.68M | 5.71 | 3.12M | +12.58% | +$15.04M | 0.01 | |
| Sofinnova | $120.48M | 5.11 | 2.79M | -19.42% | -$29.03M | 0.25 |